×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:SIOX

Sio Gene Therapies News Headlines

$0.33
-0.03 (-8.33%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.33
$0.38
50-Day Range
$0.25
$0.60
52-Week Range
$0.23
$2.95
Volume
801,909 shs
Average Volume
N/A
Market Capitalization
$24.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.20
Get Sio Gene Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SIOX and its competitors with MarketBeat's FREE daily newsletter.

SIOX Media Mentions By Week

SIOX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SIOX
News Sentiment

0.00

0.39

Average
Medical
News Sentiment

SIOX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SIOX Articles
This Week

0

0

SIOX Articles
Average Week



SIOX Stock News Headlines Today

SourceHeadline
bizjournals.com logoGene therapy firm in Durham slashes headcount as biotech stumbles
bizjournals.com - June 14 at 6:38 PM
finance.yahoo.com logoSio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
finance.yahoo.com - June 14 at 9:45 AM
markets.businessinsider.com logoMid-Afternoon Market Update: Nasdaq Jumps 400 Points; Sio Gene Therapies Shares Plummet
markets.businessinsider.com - April 28 at 5:36 PM
finance.yahoo.com logoSio Gene Therapies Ditches Two Remaining Programs, Seeks Buyer(s), Shares Plunge
finance.yahoo.com - April 28 at 12:36 PM
finance.yahoo.com logoSio Gene Therapies Provides Corporate Update
finance.yahoo.com - April 27 at 9:08 PM
finance.yahoo.com logoSio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results
finance.yahoo.com - February 11 at 7:33 AM
benzinga.com logoSVB Leerink Downgrades Sio Gene Therapies to Market Perform, Lowers Price Target to $1
benzinga.com - February 2 at 8:43 AM
benzinga.com logoHC Wainwright & Co. Maintains Buy on Sio Gene Therapies, Lowers Price Target to $7
benzinga.com - February 1 at 11:30 PM
msn.com logoThe Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
msn.com - February 1 at 1:21 PM
nasdaq.com logoCompanies Like Sio Gene Therapies (NASDAQ:SIOX) Are In A Position To Invest In Growth
nasdaq.com - January 4 at 1:42 PM
finance.yahoo.com logoWe're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely
finance.yahoo.com - November 12 at 1:49 PM
nasdaq.com logoGreat news for Sio Gene Therapies Inc. (NASDAQ:SIOX): Insiders acquired stock in large numbers last year
nasdaq.com - November 5 at 1:53 PM
finance.yahoo.com logoSio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis
finance.yahoo.com - November 1 at 7:14 AM
marketwatch.com logoSio Gene Therapies Gets FDA Fast-Track Designation for AXO-AAV-GM1 in GM1 Gangliosidosis >SIOX
marketwatch.com - October 23 at 1:38 AM
msn.com logoSio Gene Shares Gain As Genetic Nerve Cell Disorder Gene Therapy Trial Shows Encouraging Action
msn.com - October 21 at 8:36 AM
finance.yahoo.com logoSio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis
finance.yahoo.com - October 21 at 8:36 AM
finance.yahoo.com logoSio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis
finance.yahoo.com - October 21 at 8:36 AM
finance.yahoo.com logoSio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
finance.yahoo.com - October 4 at 9:35 AM
finance.yahoo.com logoUPDATE: Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
finance.yahoo.com - October 4 at 9:35 AM
finance.yahoo.com logoQuite a few insiders invested in Sio Gene Therapies Inc. (NASDAQ:SIOX) last year which is positive news for shareholders
finance.yahoo.com - September 13 at 5:28 PM
finance.yahoo.com logoSio Gene Therapies Announces Dosing of First GM1 Gangliosidosis Early Infantile (Type I) Patient in Ongoing Phase 1/2 Study of AXO-AAV-GM1 Gene Therapy
finance.yahoo.com - September 9 at 7:34 AM
nasdaq.com logoWhat Is The Ownership Structure Like For Sio Gene Therapies Inc. (NASDAQ:SIOX)?
nasdaq.com - September 6 at 4:12 PM
nasdaq.com logoSio Gene Therapies Inc Shares Close in on 52-Week Low - Market Mover
nasdaq.com - August 18 at 9:44 PM
barrons.com logoSio Gene Therapies Inc.
barrons.com - August 5 at 9:29 PM
finance.yahoo.com logoHow Many Sio Gene Therapies Inc. (NASDAQ:SIOX) Shares Do Institutions Own?
finance.yahoo.com - July 13 at 9:37 PM
nasdaq.com logoAre Options Traders Betting on a Big Move in Sio Gene Therapies (SIOX) Stock?
nasdaq.com - May 25 at 11:46 AM
finance.yahoo.com logoWe Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully
finance.yahoo.com - May 14 at 11:45 AM
benzinga.com logoSio Gene Therapies' GM1 Gangliosidosis Gene Therapy Candidate Shows Substrate Reduction In CSF
benzinga.com - May 13 at 1:18 PM
finance.yahoo.com logoSio Gene Therapies Announces CSF Reductions in GM1 Ganglioside from Clinical Trial of AXO-AAV-GM1 Gene Therapy
finance.yahoo.com - May 13 at 8:18 AM
nasdaq.com logoHave Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares This Year?
nasdaq.com - May 7 at 1:15 PM
finance.yahoo.com logoSio Gene Therapies to Participate in Upcoming Conferences
finance.yahoo.com - March 29 at 8:37 AM
finance.yahoo.com logoSio Gene Therapies Inc (SIOX) CEO Pavan Cheruvu Bought $248,000 of Shares
finance.yahoo.com - March 24 at 11:40 PM
finance.yahoo.com logoHow Many Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares Did Insiders Buy, In The Last Year?
finance.yahoo.com - March 15 at 6:35 PM
finance.yahoo.com logoSio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones
finance.yahoo.com - March 15 at 8:33 AM
finance.yahoo.com logoSio Gene Therapies to Participate in Upcoming Investor & Scientific Conferences
finance.yahoo.com - March 11 at 9:09 AM
finance.yahoo.com logoSio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 16 at 8:35 AM
finance.yahoo.com logoSio Gene Therapies Announces Financial Results for Third Fiscal Quarter Ended December 31, 2020
finance.yahoo.com - February 9 at 8:09 AM
finance.yahoo.com logoSio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle Therapeutics
finance.yahoo.com - February 4 at 7:44 AM
finance.yahoo.com logoAre Institutions Heavily Invested In Sio Gene Therapies, Inc.'s (NASDAQ:SIOX) Shares?
finance.yahoo.com - January 12 at 3:13 PM
finance.yahoo.com logoSio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1 for GM1 Gangliosidosis
finance.yahoo.com - December 15 at 6:55 PM
finance.yahoo.com logoSio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangliosidosis
finance.yahoo.com - December 2 at 7:39 AM
nasdaq.com logoSio Gene Therapies Inc. Common Stock (SIOX)
nasdaq.com - November 29 at 9:25 PM
reuters.com logoSio Gene Therapies Inc
reuters.com - November 27 at 9:51 PM
finance.yahoo.com logoSio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific Advisor
finance.yahoo.com - November 19 at 9:35 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axovant Gene Therapies Ltd. - AXGT
finance.yahoo.com - November 14 at 10:50 PM
finance.yahoo.com logoSio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020
finance.yahoo.com - November 13 at 9:59 AM
finance.yahoo.com logoHere's Why We're A Bit Worried About Axovant Gene Therapies' (NASDAQ:AXGT) Cash Burn Situation
finance.yahoo.com - November 12 at 7:49 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axovant Gene Therapies Ltd. - AXGT
finance.yahoo.com - November 11 at 10:01 AM
seekingalpha.com logoAxovant Gene Therapies to become Sio Gene Therapies November 13
seekingalpha.com - November 10 at 8:52 AM
finance.yahoo.com logoAxovant Gene Therapies Announces Name Change to Sio Gene Therapies
finance.yahoo.com - November 10 at 8:52 AM
Get Sio Gene Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SIOX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:SIOX) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.